Zydus Life Science , a global pharmaceutical company, has announced that its U.S.-based subsidiary, Sentynl Therapeutics, has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for CUTX-101. This development marks a significant milestone in the company's efforts to bring a new treatment for Menkes disease to the market.

FDA Response and Next Steps

The FDA's Complete Response Letter primarily focuses on manufacturing concerns rather than the drug's efficacy or safety profile. Specifically, the agency mentioned the need for a Current Good Manufacturing Practice (CGMP) inspection of the facility where CUTX-101 is produced.

Zydus Lifesciences has already provided responses to the FDA's re-inspection, demonstrating the facility's CGMP compliance. The company is currently awaiting the FDA's Establishment Inspection Report (EIR).

Matt Heck, CEO of Sentynl Therapeutics, stated, "We recognize the FDA's decision and remain dedicated to working with the Agency to clarify next steps. Our commitment to patients is unchanged. We believe in the promise of our therapy and are prepared to address the feedback and pursue resubmission promptly."

About CUTX-101 and Menkes Disease

CUTX-101 is a subcutaneous injectable formulation of copper histidinate designed to treat Menkes disease, a rare X-linked recessive pediatric genetic disorder. The condition affects an estimated 1 in 34,810 to 1 in 8,664 live male births and is characterized by the body's inability to absorb dietary copper effectively.

Patients with Menkes disease experience impaired copper transport across the blood-brain barrier, leading to distinctive clinical features such as:

• Sparse and depigmented hair
• Connective tissue problems
• Severe neurological symptoms

Without treatment, mortality is high, with many patients succumbing to the disease between 2-3 years of age.

Clinical Efficacy and Regulatory Status

The CUTX-101 NDA was initially granted Priority Review by the FDA, supported by positive topline clinical efficacy results. These results demonstrated a significant improvement in overall survival for Menkes disease patients who received early treatment with CUTX-101.

It's important to note that the FDA's Complete Response Letter did not cite any concerns regarding the drug's efficacy or safety data. This suggests that the primary hurdle for approval lies in addressing the manufacturing-related issues raised by the agency.

Looking Ahead

Sentynl Therapeutics plans to request a meeting with the FDA to discuss the Complete Response Letter and the resubmission of the CUTX-101 NDA. The company remains committed to bringing this potentially life-changing treatment to patients with Menkes disease.

As Zydus Lifesciences and Sentynl Therapeutics work to address the FDA's feedback, the rare disease community will be watching closely, hoping for a positive outcome that could provide a new treatment option for this devastating genetic disorder.

Zydus Life Science , a prominent pharmaceutical company, has received a significant financial reprieve as tax authorities have withdrawn a substantial tax demand. This development marks a positive turn for the company, alleviating a considerable financial liability.

Tax Demand Details

Zydus Lifesciences announced that CGST authorities have concluded proceedings on tax demands totaling ₹39.25 crore. The authorities have dropped demands worth ₹35.90 crore while confirming a liability of ₹3.35 crore plus interest and penalty.

Resolution and Remaining Liability

The company had received show-cause notices from central excise and service tax authorities regarding alleged wrongful availment of CENVAT credit on input services from March 2008 to June 2017. Following the resolution:

• The majority of the demand, amounting to ₹35.90 crore, has been dropped.
• A liability of ₹3.35 crore, plus applicable interest and penalties, has been confirmed.

Specific Demand Details

The confirmed ₹3.35 crore demand relates to CENVAT credit on sales commission paid to foreign entities, which was treated as business auxiliary services.

Company's Response

Zydus Lifesciences has stated its intention to challenge the order by filing an appeal. The company maintains that there is no material financial impact on its operations from this remaining liability.

Market Response

Following this announcement, shares of Zydus Lifesciences closed at ₹1,018.90, down 1.57%.

Implications

The withdrawal of the larger tax demand is a positive development for Zydus Lifesciences, reducing uncertainty and potentially freeing up resources that might have been set aside for tax liabilities. However, the company still faces a smaller, yet significant, tax liability of ₹3.35 crore plus interest and penalty. The company's decision to appeal this remaining demand suggests confidence in its position, but the outcome of this appeal process remains to be seen.